Adjuvant therapy in stage IIIA melanoma - Authors' reply
- PMID: 34197760
- DOI: 10.1016/S1470-2045(21)00354-5
Adjuvant therapy in stage IIIA melanoma - Authors' reply
Conflict of interest statement
AMME reports being the study chair of the EORTC 18071/CA-029 phase 3 clinical trial (Bristol Myers Squibb [BMS]) and of the EORTC 1325/KEYNOTE-054 phase 3 trial (Merck Sharp & Dohme), and has worked in a consulting or advisory role and received honoraria from Biocad, Biotech, BioInvent, BMS, CatalYm, GlaxoSmithKline, IO Biotech, ISA Pharmaceuticals, Merck, Novartis, Regeneron Pharmaceuticals, Sellas, and SkylineDx. SS reports receiving grants from Merck. CR has worked in a consulting or advisory role and received honoraria from Amgen, Biothera, BMS, Merck, MSD, Novartis, Pierre Fabre, Roche, Sanofi, and Ultimovacs.
Comment on
-
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.Lancet Oncol. 2021 May;22(5):643-654. doi: 10.1016/S1470-2045(21)00065-6. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857412 Clinical Trial.
-
Adjuvant therapy in stage IIIA melanoma.Lancet Oncol. 2021 Jul;22(7):e299. doi: 10.1016/S1470-2045(21)00346-6. Lancet Oncol. 2021. PMID: 34197759 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
